The BSH Guidelines Official Podcast

During this podcast, Anna Godfrey discusses the Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations Guideline, published in 2025.

During this podcast, Dr Austin Kulasekararaj and Dr Lugain Abdalla discuss the Guidelines for the diagnosis and management of adult aplastic anaemia, published in 2024.

Dr Tracey Chan and Dr Dima El-Sharkawi discuss the Updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children, published in 2025.

Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford. He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 170 peer-review articles on lymphoma and CLL. He is the chair of the low-grade lymphoma clinical trial research group and a core member several lymphoma study groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes and the lead author for the new ESMO Lymphoma guidelines. ​He is also an Associate Editor at the British Journal of Haematology.

Dr Deepa J. Arachchillage and Dr Jenny Tam present a review of the Guidelines on the investigation and management of antiphospholipid syndrome. Published: 04 August 2025

Professor Christopher Fox, Dr Sridhar Chaganti and Dr Bernard Maybury discuss the Management of relapsed or refractory large B-cell lymphoma Guideline, published in 2025.

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting. The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience. In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD). Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth. He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Dr Dima El-Sharkawi is a Consultant Haematologist at the Royal Marsden Hospital in Sutton. Her special interests are in CLL, rare leukaemias and lymphomas as well as early phase trials and drug development. She has been an investigator on a number of clinical research studies in these disease groups. She is clinical lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at The Royal Marsden. She is a member of the UK lymphoma research group and CLL trials groups and has co-authored national guidelines for the diagnosis and management of T cell lymphoma and Waldenstrom macroglobulinaemia.

In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment. Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.

In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025. He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.

Dr Sridhar Chaganti discusses the use of bispecific T-cell engagers (BITE’s) in large B-cell lymphoma. Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematological malignancies, lymphomas, stem cell transplantation and cellular therapies.

Dr Duncan Murray discusses mycosis fungoides and sezary syndrome. Dr Murray completed his PhD at the University of Birmingham, looking at the interaction between the immune system and malignant T cells in skin lymphoma. He finds the interaction between a "good" and "bad" T cell fascinating. He has used multiple single-cell laboratory techniques to tease apart the two populations (including V-beta antibodies, single-cell T-cell receptor (TCR) and ribonucleic acid (RNA) sequencing and mass cytometry). Skin lymphoma is an unusual disease in that key determinants of the patient's outcome sit very close together. Both anatomically and in phenotype. His current work focuses on what we can learn from high-dimensional single-cell data and the bioinformatic process to assist this.

Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options. He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients. Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.